We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Initiates Coverage of Retractable Technologies With Underperform Recommendation
Read MoreHide Full Article
Zacks Investment Research has recently initiated coverage of Retractable Technologies, Inc. (RVP - Free Report) , assigning an "Underperform" recommendation to the company's shares. This bearish stance reflects significant concerns over the company’s recent financial performance and operational challenges.
Retractable Technologies, based in Little Elm, TX, manufactures and markets safety medical products, predominantly syringes and needles, for the healthcare industry. Its offerings are primarily aimed at reducing needlestick injuries and preventing cross-contamination through reuse.
In the first quarter of 2025, Retractable Technologies reported an operating loss of $4.7 million, which widened from a loss of $2.9 million a year earlier. The losses were primarily due to elevated tariffs and rising costs associated with transitioning to domestic manufacturing. Though a temporary tariff relief agreement in May has slightly eased the pressure, the damage was already visible in RVP’s margins. Compounding the loss was a $7.2 million unrealized decline in the value of the company’s securities portfolio, pushing the quarterly net loss to $10.5 million.
On the financial front, Retractable Technologies’ cash position declined to $3.4 million at the end of March 2025 from $4.2 million at the end of 2024. However, it holds $32.3 million in tradable securities that can serve as a liquidity buffer.
The research report highlights several key factors that could dampen Retractable Technologies’ future growth. These include its rising concentration risk, especially in a volatile pricing and contracting environment, and declining average selling prices. RVP’s exposure to the shifting global manufacturing landscape and long-term growth uncertainty post-COVID windfall are additional challenges.
However, potential investors should consider certain positives outlined in the report. Retractable Technologies has made notable progress in reducing its reliance on Chinese imports — down to 62.7% in first-quarter 2025 from 90.4% a year earlier — through equipment upgrades and workforce expansion at its Texas facility. RVP also benefits from over $81 million in funding through a U.S. government Technology Investment Agreement, which supports its infrastructure buildout and generates $1.5 million in non-operating income per quarter.
Retractable Technologies’ stock has significantly underperformed its industry peers and the broader market over the past year. The valuation metrics for the company indicate that investors are pricing it at high risk and have low confidence in RVP’s future earnings and growth potential.
For a comprehensive analysis of Retractable Technologies’ financial health, strategic initiatives, and market positioning, you are encouraged to view the full Zacks research report. This in-depth report provides a detailed discussion of the company's operational strategies, financial performance, and the potential risks and opportunities that lie ahead.
Note: Our initiation of coverage on Retractable Technologies, which has a modest market capitalization of $19.8 million, aims to equip investors with the information needed to make informed decisions in this promising but inherently risky segment of the market.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Initiates Coverage of Retractable Technologies With Underperform Recommendation
Zacks Investment Research has recently initiated coverage of Retractable Technologies, Inc. (RVP - Free Report) , assigning an "Underperform" recommendation to the company's shares. This bearish stance reflects significant concerns over the company’s recent financial performance and operational challenges.
Retractable Technologies, based in Little Elm, TX, manufactures and markets safety medical products, predominantly syringes and needles, for the healthcare industry. Its offerings are primarily aimed at reducing needlestick injuries and preventing cross-contamination through reuse.
In the first quarter of 2025, Retractable Technologies reported an operating loss of $4.7 million, which widened from a loss of $2.9 million a year earlier. The losses were primarily due to elevated tariffs and rising costs associated with transitioning to domestic manufacturing. Though a temporary tariff relief agreement in May has slightly eased the pressure, the damage was already visible in RVP’s margins. Compounding the loss was a $7.2 million unrealized decline in the value of the company’s securities portfolio, pushing the quarterly net loss to $10.5 million.
On the financial front, Retractable Technologies’ cash position declined to $3.4 million at the end of March 2025 from $4.2 million at the end of 2024. However, it holds $32.3 million in tradable securities that can serve as a liquidity buffer.
The research report highlights several key factors that could dampen Retractable Technologies’ future growth. These include its rising concentration risk, especially in a volatile pricing and contracting environment, and declining average selling prices. RVP’s exposure to the shifting global manufacturing landscape and long-term growth uncertainty post-COVID windfall are additional challenges.
However, potential investors should consider certain positives outlined in the report. Retractable Technologies has made notable progress in reducing its reliance on Chinese imports — down to 62.7% in first-quarter 2025 from 90.4% a year earlier — through equipment upgrades and workforce expansion at its Texas facility. RVP also benefits from over $81 million in funding through a U.S. government Technology Investment Agreement, which supports its infrastructure buildout and generates $1.5 million in non-operating income per quarter.
Retractable Technologies’ stock has significantly underperformed its industry peers and the broader market over the past year. The valuation metrics for the company indicate that investors are pricing it at high risk and have low confidence in RVP’s future earnings and growth potential.
For a comprehensive analysis of Retractable Technologies’ financial health, strategic initiatives, and market positioning, you are encouraged to view the full Zacks research report. This in-depth report provides a detailed discussion of the company's operational strategies, financial performance, and the potential risks and opportunities that lie ahead.
Read the full Research Report on Retractable Technologies here>>>
Note: Our initiation of coverage on Retractable Technologies, which has a modest market capitalization of $19.8 million, aims to equip investors with the information needed to make informed decisions in this promising but inherently risky segment of the market.